BenzingaMon, 11 May 2026 17:57:59 GMTInhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer StudyINBX-0.52%
MarketBeatMon, 11 May 2026 16:09:25 GMTInhibrx Biosciences' INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer StudyINBX-0.52%
BarronsMon, 11 May 2026 12:26:00 GMTThis Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.INBX-0.52%
Zacks Investment ResearchThu, 23 Apr 2026 14:36:26 GMTINBX Stock Up on Upbeat Clinical Update From Colorectal Cancer StudyINBX-0.52%
Seeking AlphaWed, 22 Apr 2026 21:36:07 GMTInhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can ContinueINBX-0.52%
BenzingaWed, 22 Apr 2026 18:20:53 GMTLarge Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock SurgesINBX-0.52%
